Previous 10 | Next 10 |
home / stock / argnf / argnf news
2023-07-21 13:01:14 ET Summary argenx has released preliminary results from the ADHERE trial, which tested VYVGART Hytrulo on adults with chronic inflammatory demyelinating polyneuropathy (CIDP), where the trial results were positive. The trial, involving 322 adult patients, found...
July 20 , 202 3 Amsterdam , the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast ...
Regulated information — Inside information July 19, 2023 , 11:58 PM C ET July 19, 2023 , 5:58 PM ET Amsterdam , the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed...
2023-07-19 17:50:15 ET Summary Immunovant, Inc. received additional validation with anti-FcRn achieved as competitor argenx achieves primary endpoint in phase 2 study using VYVGART for the treatment of patients with CIDP. Immunovant expects to release results from its phase 2b stu...
Regulated information — Inside information July 18, 2023, 9:20 PM ET July 19, 2023, 3:20 AM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people su...
Regulated information — Inside information argenx announces launch of proposed global offering July 17 , 2023 Amsterdam , the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the live...
Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG autoantibodies shown to play significant role in underlying CIDP disease biology Favorable safety and tolerability profile ...
2023-07-16 07:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Mid cap stocks generat...
First - and - only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with...
2023-06-29 21:55:49 ET Summary argenx has received approval for the subcutaneous version of efgartigimod, a drug for treating myasthenia gravis, but the market did not respond positively to the news, and the company's share price remained relatively stable. The drug's label did no...
News, Short Squeeze, Breakout and More Instantly...
July 18, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, Ju...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the Netherlands— ...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN) patients ADHERE+ data show durability of functional improvements with VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) , w...